491 related articles for article (PubMed ID: 37382458)
1. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
Mendoza FA; Allawh T; Jimenez SA
Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
[TBL] [Abstract][Full Text] [Related]
2. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
3. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
Vonk MC; Smith V; Sfikakis PP; Cutolo M; Del Galdo F; Seibold JR
Autoimmun Rev; 2021 Dec; 20(12):102978. PubMed ID: 34718159
[TBL] [Abstract][Full Text] [Related]
5. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
Aringer M; Koschel D; Krause A; Schneider U; Gläser S
Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
[TBL] [Abstract][Full Text] [Related]
6. Should we use nintedanib as early therapy in patients with SSc-ILD?
Zanatta E; Moccaldi B; Szucs G; Spagnolo P
Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
8. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
[No Abstract] [Full Text] [Related]
10. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
11. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
[TBL] [Abstract][Full Text] [Related]
12. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the management of systemic sclerosis-associated interstitial lung disease.
Hoffmann-Vold AM; Distler O; Crestani B; Antoniou KM
Curr Opin Pulm Med; 2022 Sep; 28(5):441-447. PubMed ID: 35855572
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
16. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
19. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
20. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
